SCYNEXIS says Phase 3 trial for ibrexafungerp met main goal in vaginal yeast infection
SCYNEXIS (NASDAQ:SCYX) introduced on Thursday that the corporate’s Part 3 CANDLE examine for the fungicidal agent, ...
SCYNEXIS (NASDAQ:SCYX) introduced on Thursday that the corporate’s Part 3 CANDLE examine for the fungicidal agent, ...
Copyright © 2021 198 Brazil News.
All Rights Reserved.
Copyright © 2021 198 Brazil News.
All Rights Reserved.